Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Regulatory News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.10
Bid: 8.70
Ask: 9.50
Change: -0.15 (-1.62%)
Spread: 0.80 (9.195%)
Open: 9.25
High: 9.25
Low: 9.10
Prev. Close: 9.25
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

23 Apr 2018 12:43

RNS Number : 8024L
Scancell Holdings Plc
23 April 2018
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

 

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

SCANCELL HOLDINGS PLC

 

Non-UK issuer

 

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

 

An acquisition or disposal of financial instruments

 

An event changing the breakdown of voting rights

X

Other (please specify)iii:

 

3. Details of person subject to the notification obligationiv

Name

Hygea vct plc

City and country of registered office (if applicable)

London, England

4. Full name of shareholder(s) (if different from 3.)v

Name

 

City and country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reachedvi:

18 April 2018

6. Date on which issuer notified (DD/MM/YYYY):

20 April 2018

7. Total positions of person(s) subject to the notification obligation

 

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

3.5%

0%

3.5%

374,469,098

Position of previous notification (if

applicable)

4.2%

 

 

 

       

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Ordinary Shares

13,149,730

 

3.5%

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. A

 

 

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. B 1

 

 

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8.B.2

 

 

 

 

 

          

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

 

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

 

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Hygea vct plc

3.5%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

10. In case of proxy voting, please identify:

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

 

11. Additional informationxvi

 

     

 

Place of completion

London, England

Date of completion

18 April 2018

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLLLFVLSDIVFIT
Date   Source Headline
15th May 20147:30 amRNSPresents latest SCIB1 data at ASCO
9th May 20148:30 amRNSDirectorate Change
1st May 20147:00 amRNSDr Sally Adams to Join as Development Director
4th Apr 20147:00 amRNSScancell to present SCIB1 at AACR
21st Mar 20147:00 amRNS8mg Higher Dose SCIB1 Study On Track
18th Feb 20147:00 amRNSPublication of Moditope Patent
11th Feb 20147:00 amRNSSCIB1 Granted FDA Orphan Drug Status
10th Feb 20144:43 pmRNSHolding(s) in Company
6th Jan 20147:00 amRNSNottingham Technology Grant
16th Dec 20137:00 amRNSNottingham Trent University Cancer Protein Study
12th Dec 20137:00 amRNSDNA ImmunoBody Patent Granted in Japan
11th Dec 20137:00 amRNSDirector/PDMR Shareholding
9th Dec 20137:00 amRNSNew data for SCIB1 in metastatic melanoma
9th Dec 20137:00 amRNSHalf Yearly Report
18th Nov 20137:00 amRNSRe Agreement with Ichor
1st Nov 20134:56 pmRNSAGM Statement
22nd Oct 20138:00 amRNSDirector/PDMR Shareholding
14th Oct 201310:10 amRNSHolding(s) in Company
8th Oct 20132:54 pmRNSNotice of AGM
1st Oct 20137:00 amRNSInvestor Update
24th Sep 20137:00 amRNSInvestor Update Agenda
10th Sep 20133:06 pmRNSInvestor Day
3rd Sep 20137:00 amRNSDNA ImmunoBody Patent Granted in first market
20th Aug 20137:00 amRNSInclusion on Frankfurt Stock Exchange
12th Aug 20135:16 pmRNSDirector/PDMR Shareholding
8th Aug 20133:15 pmRNSHolding(s) in Company
5th Aug 20132:17 pmRNSHolding(s) in Company
1st Aug 201311:39 amRNSResult of General Meeting
26th Jul 20137:00 amRNSResult of Open Offer
23rd Jul 20137:00 amRNSDirector/PDMR Shareholding
19th Jul 20134:40 pmRNSSecond Price Monitoring Extn
19th Jul 20134:35 pmRNSPrice Monitoring Extension
12th Jul 20137:00 amRNSResearch Update
10th Jul 201310:55 amRNSAnnual Financial Report
9th Jul 20137:00 amRNSProposed Firm Placing and Open Offer
9th Jul 20137:00 amRNSFinal Results
9th Apr 20137:00 amRNSAppointment of Non-Executive Director
14th Mar 20137:00 amRNSRe: The Journal of Clinical Investigation Paper
27th Feb 20132:00 pmRNSDirectorate Change
6th Feb 20137:00 amRNSImmunoBody patent approved for grant in Japan
31st Jan 20137:00 amRNSHalf Yearly Report
29th Jan 20137:00 amRNSUpdate on patient recruitment in clinical trial
12th Dec 20127:00 amRNSDirectorate Change
12th Dec 20127:00 amRNSSCIB1 Trial-Higher Dose Allowed in Phase 1/2 Trial
6th Dec 20127:00 amRNSUpdate on SCIB1 Phase 1/2 clinical trial
3rd Dec 20129:30 amRNSHolding(s) in Company
7th Nov 20124:02 pmRNSResult of AGM
12th Oct 20127:00 amRNSFinal Results
8th Oct 201210:43 amRNSHolding(s) in Company
8th Oct 201210:43 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.